This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beringer, P. M.
Right arrow Articles by Shapiro, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beringer, P. M.
Right arrow Articles by Shapiro, B. J.

Next Article 

Antimicrobial Agents and Chemotherapy, April 2000, p. 809-813, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Pharmacokinetics of Tobramycin in Adults with Cystic Fibrosis: Implications for Once-Daily Administration

P. M. Beringer,1,2,* A. A. T. M. M. Vinks,3 R. W. Jelliffe,2,4 and B. J. Shapiro4

School of Pharmacy,1 Laboratory of Applied Pharmacokinetics,2 and School of Medicine,4 University of Southern California, Los Angeles, California, and The Hague Central Hospital Pharmacy, The Hague, The Netherlands3

Received 17 August 1998/Returned for modification 20 February 1999/Accepted 15 December 1999

Once-daily administration of aminoglycosides is routinely used in many institutions. However, comparative efficacy data for patients with cystic fibrosis (CF) are lacking. The purpose of the present study was to compare the predicted pharmacodynamic activity of tobramycin at 10 mg/kg of body weight/day administered every 24 h (q24h), q12h, and q8h. Pharmacokinetic (PK) data were derived from analysis of data on the drug concentration in sera from 60 adult CF patients. Individual maximum a posteriori probability Bayesian PK parameter values were used to construct serum concentration-versus-time curves and to determine various indices (peak concentration/MIC ratio [peak/MIC], area under the concentration-time curve/MIC ratio [AUC/MIC], and time that the concentration was less than the MIC [T<MIC]) for the three regimens described above. MICs of 1, 2, and 4 µg/ml for Pseudomonas aeruginosa were assumed in the simulations. Irrespective of the MIC, significantly lower peak/MIC but shorter T<MIC were noted when regimens of q8h versus q12h (P < 0.001), q8h versus q24h (P < 0.001), and q12h versus q24h (P < 0.001) were compared. This analysis suggests that the potential benefit of achieving a greater peak/MIC with once-daily aminoglycoside administration may be offset by the significantly greater T<MIC in CF patients compared with that achieved with multiple-daily-dosing regimens. Clinical trials are necessary to determine if once daily aminoglycoside administration is efficacious in the CF population before its routine use can be recommended.

* Corresponding author. Mailing address: School of Pharmacy, 1985 Zonal Ave., Los Angeles, CA 90033. Phone: (323) 442-5360. Fax: (626) 628-3024. E-mail: beringer{at}hsc.usc.edu.

Antimicrobial Agents and Chemotherapy, April 2000, p. 809-813, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • King, P., Lomovskaya, O., Griffith, D. C., Burns, J. L., Dudley, M. N. (2010). In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis. Antimicrob. Agents Chemother. 54: 143-148 [Abstract] [Full Text]  
  • Gibson, R. L., Burns, J. L., Ramsey, B. W. (2003). Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 168: 918-951 [Abstract] [Full Text]  
  • Aminimanizani, A., Beringer, P. M., Kang, J., Tsang, L., Jelliffe, R. W., Shapiro, B. J. (2002). Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 50: 553-559 [Abstract] [Full Text]  
  • Robinson, C. A., Kuhn, R. J. (2001). Management of Pulmonary Disease in Patients with Cystic Fibrosis. Journal of Pharmacy Practice 14: 207-227 [Abstract]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»